Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Vistagen Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 83 | 33 | −50 |
| SharesConverted for a 1-for-30 split | 1.28M | 971.8K | −308.7K (−24.1%) |
| Value | $4.79M | $1.82M | −$2.97M (−62.1%) |
New holders (4)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 101,070 | $189.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 47,696 | $89.2K | 0.01% |
| Cubist Systematic Strategies, LLC | 41,363 | $77.3K | 0.00% |
| Point72 Middle East FZE | 7,720 | $14.4K | 0.00% |
Sold out (54)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.